The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market During 2026–2030?
The chronic obstructive pulmonary disease (copd) treatment market size has seen robust expansion in recent years. It is forecast to rise from $21.73 billion in 2025 to $22.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.4%. Historically, this market’s growth can be linked to high smoking prevalence, aging population growth, increased air pollution levels, rising occupational dust exposure, and improved copd disease awareness.
The chronic obstructive pulmonary disease (copd) treatment market is projected to experience significant expansion in the coming years. Its valuation is expected to reach $29.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the forecast period is largely due to factors such as the increasing uptake of combination therapies, the broadening of homecare treatment approaches, rising healthcare expenditure, an increase in copd diagnosis rates, and advancements in inhalation drug delivery. Prominent trends for the forecast period encompass a growing adoption of triple combination inhaler therapies, an increasing move towards managing copd at home, a greater emphasis on early diagnosis and disease screening, the expansion of generic and affordable copd drugs, and a higher utilization of non-pharmacological pulmonary rehabilitation.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
Which Major Factors Are Driving The Expansion Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The increasing prevalence of smoking is projected to drive the expansion of the chronic obstructive pulmonary disease (COPD) treatment market moving forward. Smoking is defined as the inhalation of smoke, typically originating from burning substances such as tobacco, through the mouth. COPD treatment is preferred for individuals who smoke to achieve improved breathing, enhanced quality of life, reduced exacerbations, better exercise tolerance, increased longevity, and improved mental health. For instance, in July 2023, the World Health Organization, a Switzerland-based intergovernmental organization, stated that tobacco kills over 8 million people annually, a figure that includes 1.3 million non-smokers exposed to second-hand smoke. Therefore, the growing prevalence of smoking is a significant driver for the chronic obstructive pulmonary disease (COPD) treatment market’s growth.
How Are The Various Segments Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Categorized?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
What Trends Are Affecting The Expansion Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Leading companies in the chronic obstructive pulmonary disease (COPD) treatment sector are prioritizing innovative products such as Vilfuro-G to boost their market revenue. Vilfuro-G is the world’s inaugural fixed-dose triple combination medication (FDC), specifically designed for the effective treatment of chronic obstructive pulmonary disease (COPD). For instance, in November 2023, Lupin Limited, an India-based pharmaceutical company, launched Vilfuro-G. This product is offered in a single fixed dose strength, with once-daily administration recommended. The launch of Vilfuro-G is expected to significantly improve the lives of COPD patients and broaden Lupin’s respiratory product portfolio, highlighting the company’s dedication to providing advanced treatment options to patients and medical professionals. Vilfuro-G is the sole fixed-dose combination (FDC) specifically formulated to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.
Which Major Firms Influence Developments In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (copd) treatment market are Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Pfizer Inc., Mylan N.V., Orion Corporation, Cipla Limited, Glenmark Pharmaceuticals Limited, Biocon Limited, Lupin Limited, Mundipharma International Limited
Read the full chronic obstructive pulmonary disease (copd) treatment market report here:
Which Region Currently Holds The Largest Share Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2025. Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (copd) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
Browse Through More Reports Similar to the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2026, By The Business Research Company
Chronic Obstructive Pulmonary Disease Copd Treatment Market Report 2026
Chronic Obstructive Pulmonary Disease Copd And Asthma Devices Market Report 2026
Anti Asthmatics And Copd Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model